Phase III prospective randomized comparison trial of depot octreotide plus interferon Alfa-2b versus depot octreotide plus bevacizumab in patients with advanced carcinoid tumors: SWOG S0518

Journal of Clinical Oncology

Volumn 35, Issue 15, 2017, Pages 1695-1703

  Yao, James C ^a   Moran, Cesar ^a   Guthrie, Katherine A ^b   McDonough, Shannon ^b   Strosberg, Jonathan R ^c   Kulke, Matthew H ^d   Chan, Jennifer A ^d   Loconte, Noelle ^e   McWilliams, Robert R ^f   Wolin, Edward M ^g,h   Mattar, Bassam ⁱ   Chen, Helen ^j   Blanke, Charles D ^k   Hochster, Howard S ^l  

^a UNIVERSITY OF TEXAS   (United States)

^b USA   (United States)

^c H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^d DANA FARBER CANCER INSTITUTE   (United States)

^e UNIVERSITY OF WISCONSIN   (United States)

^f Mayo Clinic College of Medicine   (United States)

^g UNIVERSITY OF KENTUCKY   (United States)

^h ALBERT EINSTEIN CANCER CENTER   (United States)

ⁱ Cancer Center of Kansas   (United States)

^j NATIONAL CANCER INSTITUTE   (United States)

^k OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^l YALE CANCER CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

5 HYDROXYINDOLEACETIC ACID; ALPHA2B INTERFERON; BEVACIZUMAB; BIOLOGICAL MARKER; OCTREOTIDE; ALPHA INTERFERON; ANTINEOPLASTIC AGENT; RECOMBINANT PROTEIN;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER LOCALIZATION; CANCER PROGNOSIS; CANCER SURVIVAL; CARCINOID; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG TREATMENT FAILURE; FATIGUE; FEMALE; HEADACHE; HUMAN; HYPERTENSION; MALE; MEASUREMENT; NAUSEA; NEUTROPENIA; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; SURVIVAL RATE; TREATMENT DURATION; VERY ELDERLY; CARCINOID TUMOR; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DRUG DELIVERY SYSTEM; MIDDLE AGED; MULTICENTER STUDY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BEVACIZUMAB; CARCINOID TUMOR; DISEASE-FREE SURVIVAL; DRUG DELIVERY SYSTEMS; FEMALE; HUMANS; INTERFERON-ALPHA; MALE; MIDDLE AGED; OCTREOTIDE; RECOMBINANT PROTEINS;

EID: 85022183540     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2016.70.4072     Document Type: Article

References (24)

1. Yao JC, Hassan M, Phan A, et al: One hundred years after “carcinoid”: Epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 26: 3063-3072, 2008
2. Yao JC, Shah MH, Ito T, et al: Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 364:514-523, 2011
3. Raymond E, Dahan L, Raoul JL, et al: Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med 364:501-513, 2011
4. Caplin ME, Pavel M, Cwikla JB, et al: Lanreotide in metastatic enteropancreatic neuroendocrine tumors. N Engl J Med 371:224-233, 2014
5. Yao JC, Fazio N, Singh S, et al: Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): A randomised, placebo-controlled, phase 3 study. Lancet 387:968-977, 2016
6. Nilsson A, Janson ET, Eriksson B, et al: Levels of angiogenic peptides in sera from patients with carcinoid tumours during alpha-interferon treatment. Anticancer Res 21(6A):4087-4090, 2001
7. Terris B, Scoazec JY, Rubbia L, et al: Expression of vascular endothelial growth factor in digestive neuroendocrine tumours. Histopathology 32: 133-138, 1998
8. Zhang J, Jia Z, Li Q, et al: Elevated expression of vascular endothelial growth factor correlates with increased angiogenesis and decreased progression-free survival among patients with low-grade neuroendocrine tumors. Cancer 109:1478-1486, 2007
9. Yao JC, Phan A, Hoff PM, et al: Targeting vascular endothelial growth factor in advanced carcinoid tumor: A random assignment phase II study of depot octreotide with bevacizumab and pegylated interferon alpha-2b. J Clin Oncol 26:1316-1323, 2008
10. Berruti A, Fazio N, Ferrero A, et al: Bevacizumab plus octreotide and metronomic capecitabine in patients with metastatic well-to-moderately differentiated neuroendocrine tumors: The XELBE-VOCT study. BMC Cancer 14:184, 2014
11. Mitry E, Walter T, Baudin E, et al: Bevacizumab plus capecitabine in patients with progressive advanced well-differentiated neuroendocrine tumors of the gastro-intestinal (GI-NETs) tract (BETTER trial): A phase II nonrandomised trial. Eur J Cancer 50: 3107-3115, 2014
12. Yao JC, Phan AT, Hess K, et al: Perfusion computed tomography as functional biomarker in randomized run-in study of bevacizumab and everolimus in well-differentiated neuroendocrine tumors. Pancreas 44:190-197, 2015
13. Hobday TJ, Qin R, Reidy-Lagunes D, et al: Multicenter phase II trial of temsirolimus and bevacizumab in pancreatic neuroendocrine tumors. J Clin Oncol 33:1551-1556, 2015
14. Chan JA, Stuart K, Earle CC, et al: Prospective study of bevacizumab plus temozolomide in patients with advanced neuroendocrine tumors. J Clin Oncol 30:2963-2968, 2012
15. Schnirer II, Yao JC, Ajani JA: Carcinoid: A comprehensive review. Acta Oncol 42:672-692, 2003
16. Kölby L, Persson G, Franzén S, et al: Randomized clinical trial of the effect of interferon alpha on survival in patients with disseminated midgut carcinoid tumours. Br J Surg 90:687-693, 2003
17. NCCN Practice Guidelines in Oncology: Neuroendocrine Tumors (v.2.2005). National Comprehensive Cancer Network, 2005, pp 20
18. Pape UF, Jann H, Müller-Nordhorn J, et al: Prognostic relevance of a novel TNM classification system for upper gastroenteropancreatic neuroendocrine tumors. Cancer 113:256-265, 2008
19. Pocock SJ, Simon R: Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.Biometrics 31:103-115, 1975
20. Rinke A, Müller HH, Schade-Brittinger C, et al: Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: A report from the PROMID study group. J Clin Oncol 27:4656-4663, 2009
21. Yao JC, Pavel M, Phan AT, et al: Chromog-ranin A and neuron-specific enolase as prognostic markers in patients with advanced pNET treated with everolimus. J Clin Endocrinol Metab 96:3741-3749, 2011
22. Pavel ME, Hainsworth JD, Baudin E, et al: Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): A randomised, placebo-controlled, phase 3 study. Lancet 378:2005-2012, 2011
23. Yao JC, Lombard-Bohas C, Baudin E, et al: Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: A phase II trial. J Clin Oncol 28:69-76, 2010
24. Kulke MH, Niedzwiecki D, Foster NR, et al: Randomized phase II study of everolimus (E) versus everolimus plus bevacizumab (E+B) in patients (Pts) with locally advanced or metastatic pancreatic neuroendocrine tumors (pNET), CALGB 80701 (Alliance). J Clin Oncol 33: 2015 (suppl; abstr 4005)